Lidokain Viatris

Lidocaine, the active ingredient in Lidokain Viatris, is a local anesthetic presented as a sterile solution for epidural, intra‑arterial and intravenous use. It provides reversible nerve impulse blockade for surgical and diagnostic procedures and for pain management in adult patients.

GNH USA supplies Lidokain Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to EU quality standards and provides reliable logistics for clinical use. Customers receive full documentation, batch traceability, and regulatory support for seamless integration into care pathways.

Lidokain Viatris, a lidocaine‑based local anesthetic, is used via epidural, intra‑arterial or intravenous routes for several clinical indications. - Surgical anesthesia: provides rapid onset local anesthesia for minor to major surgical procedures. - Diagnostic procedures: facilitates painless insertion of catheters or endoscopic tools. - Pain management: delivers analgesia for acute postoperative pain or chronic pain via epidural infusion. - Obstetric analgesia: reduces pain during labor and delivery when administered epidurally.

Lidokain Viatris may cause a range of adverse reactions, varying from mild to severe, depending on dose and administration route.

Common Side Effects: - Transient tingling, numbness, or burning sensation at the injection site. - Mild hypotension or transient bradycardia that resolves spontaneously. - Headache, dizziness, or light‑headedness shortly after administration. - Nausea, vomiting, or mild gastrointestinal discomfort. - Localized swelling or erythema at the site of injection.

Serious or Rare Side Effects: - Seizures or convulsions resulting from excessive plasma lidocaine levels. - Severe allergic reactions, including anaphylaxis, with rash, swelling, and respiratory distress. - Cardiac arrhythmias such as ventricular tachycardia or prolonged QRS interval. - Methemoglobinemia, presenting as cyanosis and reduced oxygen saturation.

When using Lidokain Viatris, clinicians should observe several precautions to minimize risks and ensure optimal efficacy. - Dosage adjustment: reduce dose in patients with hepatic impairment or cardiac conduction disorders. - Allergy screening: confirm no known hypersensitivity to amide‑type local anesthetics. - Monitoring: observe cardiovascular and CNS status during and after administration. - Drug interactions: avoid concurrent use with class I antiarrhythmics that may increase toxicity. - Pregnancy and lactation: use only if benefit outweighs potential risk, as safety data are limited. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original packaging.

Lidokain Viatris can interact with other medicines, potentially altering its plasma concentration or enhancing adverse effects.

Major Interactions (Avoid): - Class I antiarrhythmics (quinidine, procainamide): increase cardiac toxicity risk. - CYP3A4 inhibitors (ketoconazole, erythromycin): raise lidocaine plasma levels. - Beta‑blockers with other local anesthetics: potentiate bradycardia and hypotension. - Lidocaine with amiodarone: synergistic effect on cardiac conduction, raising arrhythmia risk.

Moderate Interactions (Monitor Closely): - Other sodium channel blockers (mexiletine, phenytoin): additive CNS depression. - NSAIDs: may mask early tinnitus sign of toxicity. - Loop diuretics (furosemide): alter protein binding, modestly increase free lidocaine. - General anesthetics (propofol, sevoflurane): may enhance CNS depression when combined.